Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 1
1986 1
1987 2
1988 3
1990 3
1992 2
1993 1
1994 2
1995 5
1997 8
1998 9
1999 12
2000 25
2001 7
2002 5
2003 8
2004 5
2005 9
2006 5
2007 10
2008 5
2009 7
2010 13
2011 12
2012 17
2013 9
2014 8
2015 8
2016 8
2017 25
2018 19
2019 23
2020 19
2021 21
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

304 results
Results by year
Filters applied: . Clear all
Page 1
Immune-related adverse events of checkpoint inhibitors.
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Ramos-Casals M, et al. Among authors: suarez almazor me. Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6. Nat Rev Dis Primers. 2020. PMID: 32382051 Review.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Brahmer JR, et al. Among authors: suarez almazor me. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14. J Clin Oncol. 2018. PMID: 29442540 Free PMC article.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Puzanov I, et al. Among authors: suarez almazor me. J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z. J Immunother Cancer. 2017. PMID: 29162153 Free PMC article.
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Safa H, et al. Among authors: suarez almazor me. J Immunother Cancer. 2019 Nov 21;7(1):319. doi: 10.1186/s40425-019-0774-y. J Immunother Cancer. 2019. PMID: 31753014 Free PMC article. Review.
Reply.
Tummala S, Pundole X, Aldrich J, Suarez-Almazor ME. Tummala S, et al. Among authors: suarez almazor me. Arthritis Rheumatol. 2021 Aug;73(8):1564. doi: 10.1002/art.41714. Epub 2021 Jun 29. Arthritis Rheumatol. 2021. PMID: 33682370 No abstract available.
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology. Petty RE, et al. Among authors: suarez almazor me. J Rheumatol. 2004 Feb;31(2):390-2. J Rheumatol. 2004. PMID: 14760812 No abstract available.
Reply.
Lopez-Olivo MA, Pratt G, Suarez-Almazor ME, Colmegna I, Karpes AR, Ruyu Qi S, Zamora NV, Sharma R. Lopez-Olivo MA, et al. Among authors: suarez almazor me. Arthritis Care Res (Hoboken). 2020 Dec;72(12):1828-1829. doi: 10.1002/acr.24456. Arthritis Care Res (Hoboken). 2020. PMID: 32961036 No abstract available.
304 results